Mounjaro

tirzepatide · Dual GIP / GLP-1 receptor agonist

What it is

Mounjaro is a brand name for tirzepatide, a once-weekly injectable made by Eli Lilly. It activates both the GIP and GLP-1 receptors — a dual mechanism that distinguishes it from semaglutide.

What it's used for

FDA-approved to improve blood sugar control in adults with type 2 diabetes. The same molecule is approved for weight management under the Zepbound brand.

Typical dosing schedule

Dosing schedules differ by person and are set by a prescriber. The pattern below is a commonly described escalation — it is informational only, not a recommendation.

DoseTypical timingNotes
2.5 mgWeeks 1–4Starting dose to help the body adjust.
5 mgWeeks 5–8First therapeutic dose.
7.5 mgAs directedStep up if needed and tolerated.
10 mgAs directedFurther step up.
12.5–15 mgAs directedHigher maintenance doses for some patients.

Common side effects

Commonly reported side effects include nausea, diarrhea, decreased appetite, vomiting, constipation, abdominal pain, and fatigue, most often after dose increases. Many people find symptoms ease over time, but persistent or severe symptoms should always be discussed with your prescriber. See our side-effects guide for management tips members commonly share.

Rough cost

Roughly $1,000–$1,100/month at US list price without insurance; savings cards and coverage can reduce out-of-pocket cost.

Pricing varies widely. See our cost & insurance guide for savings programs, prior-authorization basics, and more.

Discuss it with the community

Read real member experiences and ask questions: